 <h1>Pegaspargase Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pegaspargase: parenteral injection</i></p><p>Side effects include:</p><p>Grade 3 or 4 reactions: Hypoalbuminemia, elevated serum aminotransferase concentrations, febrile neutropenia, hypertriglyceridemia, hyperglycemia, hyperbilirubinemia, pancreatitis, clotting study abnormalities, embolic and thrombotic events, hypersensitivity reactions. </p><p>No apparent difference in adverse effects following IV versus IM administration. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pegaspargase: injectable solution</i></p><h3>General</h3><p>The most commonly reported side effects were elevated transaminases and clinical allergic reactions to asparaginase (including bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, and urticaria).<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Hypersensitivity, urticaria, anaphylactic reaction<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Central nervous system thrombosis/hemorrhage, seizure, peripheral motor neuropathy, syncope</p><p><b>Rare</b> (less than 0.1%): Posterior reversible leukoencephalopathy syndrome </p><p><b>Frequency not reported</b>: Somnolence, tremor<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Thrombosis, embolism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Pancreatitis, diarrhea, abdominal pain, nausea</p><p><b>Common</b> (1% to 10%): Vomiting, stomatitis, ascites</p><p><b>Rare</b> (less than 0.1%): Pancreatitis necrotizing, pancreatitis hemorrhagic </p><p><b>Frequency not reported</b>: Pancreatic pseudocyst, parotitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Febrile neutropenia</p><p><b>Common</b> (1% to 10%): Coagulopathy (prolonged prothrombin time or partial thromboplastin time; or hypofibrinogenemia), anemia</p><p><b>Frequency not reported</b>: Bone marrow failure<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated transaminases</p><p><b>Common</b> (1% to 10%): Hyperbilirubinemia, hepatotoxicity, fatty liver</p><p><b>Rare</b> (0.01% to 0.1%): Hepatic necrosis, jaundice, cholestasis, hepatic failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperglycemia, weight decreased, decreased appetite</p><p><b>Frequency not reported</b>: Glucose intolerance, hyperlipidemia, hypercholesterolemia, diabetic ketoacidosis, hypoglycemia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Infections, sepsis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Pain in extremities<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Confusion<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Hypoxia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Pyrexia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Acute renal failure<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p><p><b>Frequency not reported</b>: Toxic epidermal necrolysis (TEN), cerebrovascular accident, hemorrhage, superior sagittal sinus thrombosis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?</li>
</ul><h2>More about pegaspargase</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pegaspargase Intramuscular, Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>